2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

628. Aggressive Lymphomas: Cellular Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Gene Editing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Systems-Based Hematology, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3684 Outcomes of second-line CAR T-cell therapy following frontline Pola-R-CHP vs. R-CHOP in large B-cell lymphoma

Varun Iyengar, MD, Grace Gallagher, MPH2, Parastoo B. Dahi, MD3, Sigrun Einarsdottir, MD, PhD4, Silvia Escribano Serrat, MD5, Marina Gomez-Llobell, MD6, Lorenzo Falchi, MD7, Richard J. Lin, MD, PhD8, Jennifer Kimberly Lue, M.D.9, Maria Lia Palomba, MD10, Jae H Park, MD11, Miguel-Angel Perales, MD12, Craig Sauter, MD13, Michael Scordo, MD14, Gunjan L. Shah, MD, MS15, Roni Shouval Jr, MD, PhD16, Gilles Salles I, MD, PhD17, Sarah Samorodnitsky, PhD18, Alexander P. Boardman, MD19
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Background:
Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) is standard frontline (1L) therapy for intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL). However, whether 1L polatuzumab exposure affects second-line (2L) chimeric antigen receptor T-cell (CAR-T) therapy remains unknown. Pivotal 2L CAR-T trials (ZUMA-7, TRANSFORM, BELINDA) were conducted before Pola-R-CHP adoption, with nearly all patients receiving R-CHOP. While retrospective data suggest polatuzumab bridging is effective and feasible prior to CAR-T, the impact of 1L Pola-R-CHP on outcomes has not been studied.

Methods:
We performed a retrospective, single-center study of consecutive adult patients with large B-cell lymphoma (LBCL) who received 2L CAR-T therapy between 2020-2025. Evaluated histologic subtypes included DLBCL, high-grade B-cell lymphoma (HGBCL), and other LBCL (e.g., T-cell/histiocyte-rich B-cell lymphoma). Efficacy endpoints included overall response rate (ORR) and complete response rate (CRR) at days 28 and 100 after CAR-T infusion, progression-free survival (PFS), and overall survival (OS). Safety endpoints included the incidence and severity of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS)—graded per ASTCT criteria—and immune effector cell–associated hematotoxicity (ICAHT). Survival was estimated via the Kaplan-Meier method with groups compared using log-rank tests. Predictors of survival were examined via Cox proportional hazards regression. Fisher’s exact test was used for response rates and toxicities.

Results:
We screened 256 LBCL CAR-T recipients, identifying 95 patients meeting inclusion criteria: 76 received 1L R-CHOP; 19 Pola-R-CHP. The two cohorts were well-balanced with respect to sex, transformed disease status, pre-CAR-T disease status, KPS prior to infusion, receipt of bridging therapy, and CAR-T product. Patients receiving Pola-R-CHP (vs. R-CHOP) were younger (median age 63 vs. 69 years, p=0.046) and tended to have non-GCB disease (71% vs. 51%, p=0.2). The Pola-R-CHP group trended toward higher IPI scores at initial diagnosis (4–5: 37% vs. 22%; 2-3: 58% vs. 49%; 0–1: 5% vs. 29%; p=0.1) with a shorter median time from diagnosis to CAR-T infusion (8 vs. 12 months, p<0.001). Polatuzumab-containing bridging regimens were used exclusively in the R-CHOP cohort (R-pola: 28% vs. 0%; single-agent pola: 3% vs. 0%), whereas non-polatuzumab combination chemoimmunotherapy was more common following Pola-R-CHP (42% vs. 16%).

Response rates were favorable in both cohorts. At day 28, ORR was 89% overall: 84% for Pola-R-CHP vs. 91% for R-CHOP (p=0.4) with corresponding CRRs of 63% vs. 67% (p=0.7). At day 100, ORR was lower among those who received Pola-R-CHP (53% vs. 82%, p=0.02; CRR: 53% vs. 72%, p=0.15).

Median follow-up was 23 months. Across all patients, 12- and 24-month PFS rates were 69% (95% confidence interval [CI], 60-80%) and 51% (95% CI, 41-65%), respectively. Twelve and 24-month PFS rates were numerically lower following Pola-R-CHP (55% vs. 73%, 41% vs. 54%, p=0.09), though not statistically significant. Among all patients, 12- and 24-month OS rates were 85% (95% CI, 77–93%) and 73% (95% CI, 63–84%), respectively, while 12- and 24-month OS were again numerically lower after Pola-R-CHP (73% vs. 87%, 58% vs. 76%, p=0.13). On univariable analysis, neither 1L regimen nor cell of origin predicted survival, while higher IPI was associated with inferior PFS (4-5: HR [vs 0-1] 3.7, 95% CI, 1.3-10.7; 2-3: HR [vs. 0-1] 2.5, 95% CI, 1.0-6.6; p=0.03) and OS (4-5: HR 8.1, 95% CI, 1.8-36.9; 2-3: HR 1.6, 95% CI, 0.3-7.8; p=0.001).

CRS occurred at similar rates in both groups: 58% for Pola-R-CHP vs. 55% for R-CHOP (p=0.8; grade≥3 [G3+]: 0% vs. 1%). Rates of ICANS were also comparable: 16% vs. 18% (p>0.9; G3+: 5% vs. 5%). Early thrombocytopenic-ICAHT occurred in 36% of Pola-R-CHP vs. 20% of R-CHOP patients (p=0.1; G3+: 21% vs. 6%), and neutropenic-ICAHT occurred in 84% vs. 70% (p=0.4; G3+: 21% vs. 14%).

Discussion:
This is the first study evaluating 2L CAR-T outcomes following 1L Pola-R-CHP. Survival outcomes and toxicities did not differ significantly between cohorts despite enrichment for adverse disease features in the Pola-R-CHP group. The significantly lower day-100 ORR after Pola-R-CHP likely reflects these higher risk baseline characteristics. However, larger studies with longer follow-up are needed to validate these findings.

Varun Iyengar, MD: No relevant conflicts of interest to declare.